The biologics fill / finish services market is projected to grow at a CAGR of 8%, till 2035, claims Roots Analysis

Комментарии · 174 Просмотры

A number of biopharmaceutical companies are outsourcing their biologics fill / finish operations, thereby, prompting stakeholders engaged in this domain to undertake several expansion initiatives, to cater to the needs of clients around the globe.

Roots Analysis has announced the addition of “Biologics Fill Finish Services Market (3rd Edition), 2022-2035” report to its list of offerings.


Given the growing pipeline of biologics, lack of technical expertise, and huge capital investment in the installation of fill / finish equipment, a number of drug manufacturers are turning to contract service providers in order to ensure the development of quality drug products. This evident surge in the demand for biologics fill / finish services has presented lucrative opportunities for service providers having necessary fill / finish capabilities.




Key Market Insights


More than 175 service providers claim to offer services for biologic fill / finish operations

The biologics fill / finish market is highly fragmented, featuring a mix of small, mid-sized, and large players. It is worth noting that this market is currently dominated by mid-sized companies (having 51-500 employees), which represent more than 40% of the industry stakeholders, worldwide.


Several partnerships have been established in the biologics fill / finish services domain, since 2013

Nearly 40% of the deals were inked in 2020. Majority of the instances captured in the report were service agreements (60%). In addition, more than 50 deals have been inked by players to offer biologics fill / finish services for vaccines.


Over 170 expansions have been reported in biologics fill / finish services domain, since 2013

More than 50% of the total expansions were focused on enhancing the dedicated capacities, thereby enabling the industry stakeholders to accommodate their growing business and address the surge in the demand for fill / finish services. Further, more than 45% of the expansions involved the establishment of new plant / facilities or adding area to the existing facilities, across different geographical locations.     


The currently available biologics fill / finish capacity is estimated to be over 185 Kiloliters

 Around 90% of the installed fill / finish capacity belongs to the companies with commercial scale production capabilities. In fact, close to 85% of the available capacity belongs to the large companies (having more than 500 employees).


The demand for biologics fill / finish services is expected to grow at an annualized rate of 14%

Currently, more than 60% of the overall demand for biologics fill/ finish services is generated from filling of vials. Moreover, close to 40% of the demand is likely to be generated in the Europe region.


Europe and Asia-Pacific are expected to capture more than 70% of the market share by 2035

In terms of type of biologics, antibodies and vaccines are expected to occupy a larger share (~70%) of the total biologics fill / finish services market in 2035. Further, over 25% of the biologics fill / finish services market share for therapeutic areas is captured by oncological disorders.


To request a sample copy / brochure of this report, please visit this


Key Questions Answered

  • What is fill / finish?
  • Who are the key players offering biologics fill / finish services?
  • Where are biologics fill / finish facilities located?
  • What is the market share of ampoules, cartridges, vials, and syringes in fill / finish?
  • What types of expansion initiatives are being undertaken by players in this domain?
  • What is the current demand for biologics fill / finish services?
  • What is the current and future market size for biologics fill / finish services?


The financial opportunity within the biologics fill / finish services market has been analyzed across the following segments:


  • Type of Packaging Container
  • Ampoules
  • Cartridges
  • Syringes
  • Vials


  • Type of Biologic
  • Antibodies
  • Cell Therapies
  • Gene Therapies
  • Oligonucleotides
  • Proteins / Peptides
  • Vaccines
  • Others


  • Therapeutic Area
  • Oncological Disorders
  • Autoimmune Disorders
  • Infectious Diseases
  • Cardiovascular Disorders
  • Other Disorders


  • Scale of Operation
  • Preclinical / Clinical
  • Commercial


  • Company Size
  • Large
  • Mid-sized
  • Small


  • Key Geographical Regions
  • North America
  • Europe
  • Asia-Pacific
  • Middle East and North Africa
  • Latin America


The report features inputs from eminent industry stakeholders, according to whom, a significant increase in the demand for cell and gene therapies is driving the growth of the biologics fill / finish market. The report includes detailed transcripts of discussions held with the following experts:


  • Gregor Kawaletz (Chief Commercial Officer, IDT Biologika)
  • Matt Delaney (Vice President Business Development Marketing, Cytovance Biologics)
  • Purushottam Singnurkar (Research Director and Head of Formulation Development, Syngene International)
  • Ales Sima (Business Development Manager, Oncomed Manufacturing)
  • Amit Chandra (Technology Watch Manager, Yposkesi)
  • Jos Vergeest (International Business Developer, HALIX)


The research also includes detailed profiles of key players (listed below) engaged in offering biologics fill / finish services; each profile features a brief overview of the company, its financial information (if available), details on biologics fill / finish services, location of facilities recent developments and an informed future outlook.


  • AbbVie Contract Manufacturing
  • Asymchem
  • BioReliance
  • Boehringer Ingelheim BioXcellence
  • Catalent Biologics
  • Charles River Laboratories
  • Fareva
  • Fresenius Kabi
  • Glaxo SmithKline
  • Hetero Drugs
  • Intas Pharmaceuticals
  • Lonza
  • Patheon
  • Pierre Fabre
  • Recipharm
  • Samsun Biologics
  • Syngene
  • Takara Bio
  • Wacker Biotech
  • WuXi AppTec
  • WuXi Biologics


For additional details, please visit or email


You may also be interested in the following titles:

  1. Smart Labels Market: Industry Trends and Global Forecasts, 2022-2035
  2. AI-based Digital Pathology / AI Pathology Market: Industry Trends and Global Forecasts, 2022-2035

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.



Ben Johnson

+1 (415) 800 3415

Показать полностью...